Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for VIVUS, Inc. (VVUSQ : OTC)
 
 • Company Description   
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $ Daily Weekly Monthly
20 Day Moving Average: shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta:
52 Week High: $0.50
52 Week Low: $0.07
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week % %
12 Week % %
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
900 E. HAMILTON AVENUE SUITE 550
-
CAMPBELL,CA 95008
USA
ph: 650-934-5200
fax: 650-934-5389
ir@vivus.com http://www.vivus.com
 
 • General Corporate Information   
Officers
John P. Amos - Chief Executive Officer and Director
David Y. Norton - Chairman of the Board of Directors
Mark K. Oki - Senior Vice President; Chief Financial Officer and
Karen Ferrell - Director
Edward A. Kangas - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 928551308
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding:
Most Recent Split Date: 9.00 (0.10:1)
Beta:
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: %
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/23 - -
12/31/22 - -
09/30/22 - -
ROA
03/31/23 - -
12/31/22 - -
09/30/22 - -
Current Ratio
03/31/23 - -
12/31/22 - -
09/30/22 - -
Quick Ratio
03/31/23 - -
12/31/22 - -
09/30/22 - -
Operating Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Net Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Pre-Tax Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Book Value
03/31/23 - -
12/31/22 - -
09/30/22 - -
Inventory Turnover
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Capital
03/31/23 - -
12/31/22 - -
09/30/22 - -
 

Powered by Zacks Investment Research ©